共 76 条
[1]
Bartlett JM(2001)Evaluating HER2 amplification and overexpression in breast cancer J Pathol 195 422-428
[2]
Going JJ(2003)The clinical evaluation of HER-2 status: which test to use? J Pathol 199 411-417
[3]
Mallon EA(2007)Trastuzumab–mechanism of action and use in clinical practice N Engl J Med 357 39-51
[4]
Bartlett J(2011)Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 1273-1283
[5]
Mallon E(2010)HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial J Clin Oncol 28 4307-4315
[6]
Cooke T(2013)Cancer statistics, 2013 CA Cancer J Clin 63 11-30
[7]
Hudis CA(2005)HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment Oncol Rep 13 305-309
[8]
Slamon D(1996)Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer Can Res 56 3886-3890
[9]
Eiermann W(2014)TOP2A gene copy number change in breast cancer J Clin Pathol 67 420-425
[10]
Robert N(2011)Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy J Clin Oncol 29 859-867